Pharma often accuses the NHS of being behind the curve when it comes to adopting the latest CAR-T therapies – but England's health service is already doing the groundwork to get the la
I was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was – did the company have any designs on entering the viral vector-based gene therap
Swiss pharma giant Novartis saw modest growth of 2% in 2017, with growth in Cosentyx and Entresto offsetting generic erosion to its cancer blockbuster Gleevec/Glivec.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.